Polynovo Ltd
ASX:PNV
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.34
2.72
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Polynovo Ltd
Polynovo Ltd
Capital Expenditures
Polynovo Ltd
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Polynovo Ltd
ASX:PNV
|
Capital Expenditures
-AU$2.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
15%
|
CAGR 10-Years
-43%
|
|
|
Nanosonics Ltd
ASX:NAN
|
Capital Expenditures
-AU$2.5m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-18%
|
|
|
SDI Ltd
ASX:SDI
|
Capital Expenditures
-AU$10.3m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-7%
|
|
|
Anteris Technologies Ltd
ASX:AVR
|
Capital Expenditures
-AU$3.6m
|
CAGR 3-Years
-131%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
|
Ansell Ltd
ASX:ANN
|
Capital Expenditures
-$62.8m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-2%
|
|
|
Next Science Ltd
ASX:NXS
|
Capital Expenditures
-$884.5k
|
CAGR 3-Years
-9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Polynovo Ltd
Glance View
Polynovo Ltd. engages in the provision biodegradable medical devices. The company is headquartered in Melbourne, Victoria and currently employs 122 full-time employees. The Company’s principal activity is the development of medical devices for various applications. The Company’s products include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb technology. BTM is a man-made synthetic polymer that does not contain any biologic materials. BTM is a skin treatment. NovoSorb is a polymer, which is utilizes for the manufacture of novel medical devices, such as Biocompatible polymers. These biocompatible polymers are designed to support different functions of the body and then biodegrade into by-products that can be absorbed and excreted by the body. The company can be produced in a range of formats with different mechanical and degradation properties. In addition to NovoSorb BTM, they can be used for thermoplastic extrusions, filaments for weaving or knitting and as a solution for spray or dip coatings of other devices.
See Also
What is Polynovo Ltd's Capital Expenditures?
Capital Expenditures
-2.9m
AUD
Based on the financial report for Jun 30, 2024, Polynovo Ltd's Capital Expenditures amounts to -2.9m AUD.
What is Polynovo Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-43%
Over the last year, the Capital Expenditures growth was -90%. The average annual Capital Expenditures growth rates for Polynovo Ltd have been 7% over the past three years , 15% over the past five years , and -43% over the past ten years .
You don't have any saved screeners yet
